New title displays the evolution of the Company’s business focus and its dedication to immunotherapies and vaccines
LAWRENCEVILLE, N.J., Sept. 19, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug growth firm, immediately introduced an organization title change to Imunon, Inc., reflecting the evolution of the Company’s business focus and its dedication to creating cutting-edge immunotherapies and next-generation vaccines to deal with most cancers and infectious ailments.
The Company’s widespread inventory will commerce on the Nasdaq Stock Market below the brand new ticker image “IMNN” efficient as of the opening of buying and selling on September 21, 2022. The Company has filed an modification to its Articles of Incorporation to impact the brand new company title and is introducing a brand new brand and a brand new company web site, www.imunon.com.
Imunon is establishing a management place in immunology by creating DNA-mediated therapies with a lead asset concentrating on superior ovarian most cancers. The new title higher displays the Company’s progress in immunology and emphasizes its dedication to harnessing the constructing blocks of life to work in concord with the physique’s immune system.
“Our new name, Imunon, ideally captures the essence of our scientific endeavors and our mission,” mentioned Dr. Corinne Le Goff, president and CEO of Imunon. “With this name change, we are underscoring our commitment to create a new category of medicines leveraging our proprietary plasmid DNA technology platform in the fields of immuno-oncology and vaccines. With a strong balance sheet supporting current operations into 2025, we are well positioned to build a differentiated company to deliver on the promise of our gene-based therapies.”
About Imunon Inc.
Imunon is a totally built-in, medical stage biotechnology firm targeted on advancing a portfolio of progressive therapies that harness the physique’s pure mechanisms to generate secure, efficient and sturdy responses throughout a broad array of human ailments, constituting a differentiating strategy from typical therapies.
Imunon has two platform applied sciences: Our TheraPlas® platform for the event of immunotherapies and different anti-cancer nucleic acid-based therapies, and our PLACCINE platform for the event of nucleic acid vaccines for infectious ailments and most cancers. The Company’s lead medical program, GEN-1, is a DNA-based immunotherapy for the localized therapy of superior ovarian most cancers presently in Phase II growth. GEN-1 works by instructing the physique to produce secure and sturdy ranges of highly effective most cancers combating molecules, resembling interleukin-12 and interferon gamma, on the tumor website. Additionally, the Company is conducting preclinical proof-of-concept research on a nucleic acid vaccine candidate concentrating on SARS-CoV-2 virus so as to validate its PLACCINE platform. Imunon’s platform applied sciences are based mostly on the supply of nucleic acids with novel artificial supply programs which might be unbiased of viral vectors or gadgets. We will proceed to leverage these platforms and to advance the technological frontier of plasmid DNA to higher serve sufferers with tough to deal with circumstances. For extra info on Imunon, go to www.imunon.com.
Forward-Looking Statements
Imunon needs to inform readers that forward-looking statements on this information launch are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements contain dangers and uncertainties together with, with out limitation, unexpected modifications in the middle of analysis and growth actions and in medical trials; the uncertainties of and difficulties in analyzing interim medical information; the numerous expense, time and threat of failure of conducting medical trials; the necessity for Imunon to consider its future growth plans; potential acquisitions or licenses of different applied sciences, property or companies; potential actions by prospects, suppliers, rivals or regulatory authorities; and different dangers detailed from time to time in Imunon’s periodic stories and prospectuses filed with the Securities and Exchange Commission. Imunon assumes no obligation to replace or complement forward-looking statements that turn into unfaithful due to subsequent occasions, new info or in any other case.
Contacts:
Jeffrey W. Church
Executive Vice President, CFO and Corporate Secretary
609-482-2455
[email protected]
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
[email protected]
# # #
